VB 1400
Alternative Names: VB-1400Latest Information Update: 14 Dec 2023
At a glance
- Originator VectivBio
- Developer Ironwood Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inborn error metabolic disorders
Most Recent Events
- 12 Dec 2023 VectivBio has been acquired and merged into Ironwood Pharmaceuticals
- 03 Feb 2022 Early research in Inborn error metabolic disorders in Switzerland (unspecified route) (VectivBio pipeline, February 2022)